<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630668</url>
  </required_header>
  <id_info>
    <org_study_id>MP-12LCHM</org_study_id>
    <nct_id>NCT01630668</nct_id>
  </id_info>
  <brief_title>Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Micropharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Micropharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: In recent years, probiotics have shown promise in treating a variety of diseases.&#xD;
      Previously, the investigators have reported on the clinical efficacy of Lactobacillus reuteri&#xD;
      NCIMB 30242 in improving the lipid profile in hypercholesterolemic adults.&#xD;
&#xD;
      Objective: The purpose of the study is to determine the lipid lowering efficacy of a&#xD;
      One-a-Day probiotic supplement capsule containing Lactobacillus reuteri NCIMB 30242 over 12&#xD;
      weeks in subjects with hypercholesterolemia.&#xD;
&#xD;
      Design: The study design is a double-blinded, placebo-controlled, randomized, parallel-arm,&#xD;
      multi-centre study. The study will last a total of 14 weeks, including a 2-week run-in period&#xD;
      and a 12-week intervention period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be the change in serum LDL-cholesterol from baseline to endpoint between control and treatment groups.</measure>
    <time_frame>Week 0 and Week 12 of intervention period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>One-a-Day L. reuteri NCIMB 30242 supplement capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>One-a-Day placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>One-a-Day L. reuteri NCIMB 30242 supplement capsule</intervention_name>
    <description>Once per day, 12 weeks</description>
    <arm_group_label>One-a-Day L. reuteri NCIMB 30242 supplement capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>One-a-Day placebo capsule</intervention_name>
    <description>Once per day, 12 weeks</description>
    <arm_group_label>One-a-Day placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Males and females, aged 20 to 75 years (bounds included).&#xD;
&#xD;
          -  LDL-C ≥ 3.40 mmol/L (&lt;15% variation between visits V0 and V2-1).&#xD;
&#xD;
          -  TG &lt; 4.00 mmol/L (confirmed at visits V0 and V2-1).&#xD;
&#xD;
          -  BMI range will be 23.0 to 32.5 kg/m2 (bounds included).&#xD;
&#xD;
          -  Subject understands and accepts to follow the dietary recommendations advisable for&#xD;
             hypercholesterolemic patients (according to NCEP-ATP III guidelines).&#xD;
&#xD;
          -  Judged by the investigators as compliant (&gt;80%) with product consumption (check at&#xD;
             V2-1), and motivated.&#xD;
&#xD;
          -  Signed informed consent form prior to inclusion in the study.&#xD;
&#xD;
          -  Note: Subjects will be permitted to take stable doses of thyroid hormone and&#xD;
             anti-hypertensive agents, as long as these are continued equivalently throughout the&#xD;
             duration of study.&#xD;
&#xD;
          -  If female, subject is not of child bearing potential. Defined as females who have had&#xD;
             a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal&#xD;
             (natural or surgically with &gt; 1 year since last menstruation). OR Female subject of&#xD;
             childbearing potential must agree to use a medically approved method of birth control&#xD;
             and have a negative urine pregnancy test result. Acceptable methods of birth control&#xD;
             include:&#xD;
&#xD;
               -  Hormonal contraceptives including oral contraceptives, hormone birth control&#xD;
                  patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable&#xD;
                  contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)&#xD;
&#xD;
               -  Intrauterine devices&#xD;
&#xD;
               -  Vasectomy of partner&#xD;
&#xD;
               -  Total abstinence&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Use of cholesterol lowering prescription drugs within the last 6 months.&#xD;
&#xD;
          -  Use of plant sterols, omega 3, fish oil, soy protein, soluble oat fiber, psyllium seed&#xD;
             husk, or other cholesterol lowering non-prescription supplements within last 1 month.&#xD;
&#xD;
          -  History of chronic use of alcohol (&gt; 2 drinks/d).&#xD;
&#xD;
          -  History of heavy smoking (≥ 20 cigarettes/d).&#xD;
&#xD;
          -  Use of systemic antibodies, corticosteroids, androgens, or phenytoin.&#xD;
&#xD;
          -  Immune-compromised subjects (e.g. AIDS, lymphoma, subjects undergoing long-term&#xD;
             corticosteroid treatment)&#xD;
&#xD;
          -  Subject having experienced any cardiovascular event (Myocardial infarction, coronary&#xD;
             artery bypass, or other major surgical procedures) in the last 6 months.&#xD;
&#xD;
          -  Subjects with elevated LDL-C (≥ 3.40 mmol/L) and high (&gt;20%) CVD risk estimated by the&#xD;
             Framingham risk score.&#xD;
&#xD;
          -  Previously diagnosed Type I or Type II diabetes.&#xD;
&#xD;
          -  Subject receiving systemic treatment or topical treatment likely to interfere with&#xD;
             evaluation of the study parameters.&#xD;
&#xD;
          -  Subject currently involved in a clinical trial or in an exclusion period following&#xD;
             participation in another clinical trial.&#xD;
&#xD;
          -  History of angina, congestive heart failure, inflammatory bowel disease, pancreatitis,&#xD;
             gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of&#xD;
             active lesions, chemotherapy or surgery in the past year).&#xD;
&#xD;
          -  Clinically significant abnormal laboratory results at screening.&#xD;
&#xD;
          -  Chronic user of probiotics or fibre laxative (greater than 2 doses/wk), or stimulant&#xD;
             laxatives.&#xD;
&#xD;
          -  History of eating disorders.&#xD;
&#xD;
          -  Exercise greater than 15 miles/wk or 4,000 kcal/wk.&#xD;
&#xD;
          -  For female subjects: Pregnancy, breast feeding, or intent to get pregnant.&#xD;
&#xD;
          -  Allergy or sensitivity to test product ingredients&#xD;
&#xD;
          -  Allergy or sensitivity to all 3 antibiotics (Clindamycin, Erythromycin and&#xD;
             Ampicillin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

